Movement Alert｜CanNova-B Rises 5.38% in Regular Trading, AbbVie 10.9 Billion Dollar Apogee Acquisition Validates Long-Acting AD Product Value

Market Focus06-23

On June 23, CanNova-B rose 5.38% in regular trading, trading at HKD 60.0/share, with turnover of HKD 58.93 million.

On the news front, AbbVie announced a planned acquisition of Apogee for approximately USD 10.9 billion, with the core asset being APG777, a long-acting IL-13 monoclonal antibody targeting atopic dermatitis (AD). The transaction is expected to close in Q3. The deal reflects multinational pharmaceutical companies' strong endorsement of the strategic value and peak sales potential of long-acting AD assets.

CanNova's pipeline product CM512 belongs to the same long-acting AD track. Analysts note that if clinical data supports extended dosing intervals, the long-acting advantage could significantly enhance its market competitiveness. Additionally, the company's core commercialized product Kangyueda has been approved for multiple indications and included in national medical insurance, with commercial scale-up progressing steadily. The medical sector showed resilience on the day, with capital focusing on innovative drug names accelerating commercialization ahead of Q2 earnings expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128880170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128880170","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CanNova-B Rises 5.38% in Regular Trading, AbbVie 10.9 Billion Dollar Apogee Acquisition Validates Long-Acting AD Product Value","media":"Market Focus","content":"<p><p>On June 23, CanNova-B rose 5.38% in regular trading, trading at HKD 60.0/share, with turnover of HKD 58.93 million.</p><p>On the news front, AbbVie announced a planned acquisition of Apogee for approximately USD 10.9 billion, with the core asset being APG777, a long-acting IL-13 monoclonal antibody targeting atopic dermatitis (AD). The transaction is expected to close in Q3. The deal reflects multinational pharmaceutical companies' strong endorsement of the strategic value and peak sales potential of long-acting AD assets.</p><p>CanNova's pipeline product CM512 belongs to the same long-acting AD track. Analysts note that if clinical data supports extended dosing intervals, the long-acting advantage could significantly enhance its market competitiveness. Additionally, the company's core commercialized product Kangyueda has been approved for multiple indications and included in national medical insurance, with commercial scale-up progressing steadily. The medical sector showed resilience on the day, with capital focusing on innovative drug names accelerating commercialization ahead of Q2 earnings expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CanNova-B Rises 5.38% in Regular Trading, AbbVie 10.9 Billion Dollar Apogee Acquisition Validates Long-Acting AD Product Value</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CanNova-B Rises 5.38% in Regular Trading, AbbVie 10.9 Billion Dollar Apogee Acquisition Validates Long-Acting AD Product Value\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 10:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, CanNova-B rose 5.38% in regular trading, trading at HKD 60.0/share, with turnover of HKD 58.93 million.</p><p>On the news front, AbbVie announced a planned acquisition of Apogee for approximately USD 10.9 billion, with the core asset being APG777, a long-acting IL-13 monoclonal antibody targeting atopic dermatitis (AD). The transaction is expected to close in Q3. The deal reflects multinational pharmaceutical companies' strong endorsement of the strategic value and peak sales potential of long-acting AD assets.</p><p>CanNova's pipeline product CM512 belongs to the same long-acting AD track. Analysts note that if clinical data supports extended dosing intervals, the long-acting advantage could significantly enhance its market competitiveness. Additionally, the company's core commercialized product Kangyueda has been approved for multiple indications and included in national medical insurance, with commercial scale-up progressing steadily. The medical sector showed resilience on the day, with capital focusing on innovative drug names accelerating commercialization ahead of Q2 earnings expectations.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1128880170","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128880170","pubTimestamp":1782181521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, CanNova-B rose 5.38% in regular trading, trading at HKD 60.0/share, with turnover of HKD 58.93 million.On the news front, AbbVie announced a planned acquisition of Apogee for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"动静提示|CanNova-B常规交易涨5.38%艾伯维109亿美元收购Apogee验证长效AD产品价值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On June 23, CanNova-B rose 5.38% in regular trading, trading at HKD 60.0/share, with turnover of HKD 58.93 million.On the news front, AbbVie announced a planned acquisition of Apogee for approximately USD 10.9 billion, with the core asset being APG777, a long-acting IL-13 monoclonal antibody targeting atopic dermatitis (AD). The transaction is expected to close in Q3. The deal reflects multinational pharmaceutical companies' strong endorsement of the strategic value and peak sales potential of long-acting AD assets.CanNova's pipeline product CM512 belongs to the same long-acting AD track. Analysts note that if clinical data supports extended dosing intervals, the long-acting advantage could significantly enhance its market competitiveness. Additionally, the company's core commercialized product Kangyueda has been approved for multiple indications and included in national medical insurance, with commercial scale-up progressing steadily. The medical sector showed resilience on the day, with capital focusing on innovative drug names accelerating commercialization ahead of Q2 earnings expectations.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128880170","isCrawlerRequest":true}